RxDoctor Payments DataLook up a doctor →

Lyssa Ochoa, MD

Vascular Surgery · San Antonio, TXNPI 1699900480

Payments from drug & device makers

$94,715in general payments, 2019–2025

Across 300 payments — averaging $315.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$51K
  • Angiodynamics, Inc.$17K
  • Janssen Scientific Affairs, LLC$11K
  • Humacyte Global, Inc.$7K
  • Endologix LLC$2K
  • Bard Peripheral Vascular, Inc.$1K
  • plus $5K from 35 others

What the payments were for

  • Consulting fees$10,80028%
  • Speaking & faculty fees$9002%
  • Travel & lodging$1,0663%
  • Food & beverage$9,10523%
  • Education$480%
  • Other$16,87543%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$94,715 in reported general payments places this provider in the 85th percentile of 347 vascular surgery providers in Texas.

See all vascular surgery providers in Texas

Medicare billing

Part B allowed, 2024
$486,275
Medicare patients
479
Services billed
1,912

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban96$77,190
EliquisApixaban29$19,766
Atorvastatin Calcium307$1,958
ClopidogrelClopidogrel Bisulfate292$1,880
Rosuvastatin Calcium208$1,722
Doxycycline Hyclate110$1,713
LokelmaSodium Zirconium Cyclosilicate12$1,620
Prasugrel Hcl18$757
Cilostazol12$231
Tramadol Hcl38$131
Levofloxacin22$59

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$646$77,19096 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 347 vascular surgery providers in Texas.

Other vascular surgery in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →